INVERNIZZI PIETRO

Ciardullo, S., Mantovani, A., Morieri, M., Muraca, E., Invernizzi, P., Perseghin, G. (2024). Impact of MASLD and MetALD on clinical outcomes: A meta-analysis of preliminary evidence. LIVER INTERNATIONAL [10.1111/liv.15939]. Detail

Ciardullo, S., Muraca, E., Vergani, M., Invernizzi, P., Perseghin, G. (2024). Advancements in pharmacological treatment of NAFLD/MASLD: a focus on metabolic and liver-targeted interventions. GASTROENTEROLOGY REPORT, 12, 1-10 [10.1093/gastro/goae029]. Detail

Cristoferi, L., Ciardullo, S., Invernizzi, P., Perseghin, G., Carbone, M. (2023). Endocrinology and Metabolic Diseases (Including Diabetes). In G.M. Hirschfield, P. Gill, J. Neuberger (a cura di), The Liver in Systemic Disease: A Clinician's Guide to Abnormal Liver Tests (pp. 99-109). Gideon M. Hirschfield, Paramjit Gill, James Neuberger [10.1002/9781119802181.ch8]. Detail

Murilloperez, C., Ioannou, S., Hassanally, I., Trivedi, P., Corpechot, C., van der Meer, A., et al. (2023). Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one-year non-responders and predicts survival. LIVER INTERNATIONAL, 43(7 (July 2023)), 1497-1506 [10.1111/liv.15592]. Detail

Hirschfield, G., Shiffman, M., Gulamhusein, A., Kowdley, K., Vierling, J., Levy, C., et al. (2023). Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study. HEPATOLOGY, 78(2), 397-415 [10.1097/HEP.0000000000000395]. Detail